Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review

Post-transplant lymphoproliferative disease (PTLD) often exhibits poor prognosis and high mortality, and there are no uniform guidelines for the treatment of this disease. Anti-CD19 chimeric antigen receptor (CAR) T cells show significant efficacy in treatment of relapse/refractory diffuse large B-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Gang, Li, Qing, Zhu, Haibo, Jiang, Yanyu, Yuan, Jijun, Fu, Yingxin, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481808/
https://www.ncbi.nlm.nih.gov/pubmed/34604065
http://dx.doi.org/10.3389/fonc.2021.726134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481808/
https://www.ncbi.nlm.nih.gov/pubmed/34604065
http://dx.doi.org/10.3389/fonc.2021.726134

Ejemplares similares